ALLENDALE, N.J., April 13, 2011 /PRNewswire/ — Progenitor Cell
Therapy (PCT), a wholly owned subsidiary of NeoStem, Inc. (NYSE
Amex:
NBS) and an internationally recognized cell therapy services
and development company, announced today that it has, once again,
demonstrated compliance with the FACT-JACIE International Standards
for Cellular Therapy Product Collection, Processing and
Administration, and has earned FACT accreditation for its
processing facilities through October 19, 2013 based on inspections
by FACT at PCT’s facilities in Allendale, New Jersey and Mountain
View, California. FACT-JACIE standards were developed in 2006 by
the Foundation for the Accreditation of Cellular Therapy and the
Joint Accreditation Committee of the International Society for
Cellular Therapy (ISCT) and the European Group for Blood and Marrow
Transplantation (EBMT).
“We recognize that clients put a great deal of trust in PCT when
they share their most critical responsibilities of product
manufacturing by contracting with PCT. We believe that PCT’s track
record of quality, timeliness and execution speaks for itself,”
said Dr. Robin Smith, Chief Executive Officer of NeoStem.
With plans to rapidly expand the manufacturing and storage
business to drive revenues from cell therapy clients as well as
internal therapeutic development, FACT accreditation for PCT is
critical to promote quality medical and laboratory practice of
cellular therapy through its peer-developed standards and voluntary
inspection and accreditation program. Adherence to such high
standards further ensures cell stability and viability and batch
consistency for the development of a cell therapy product.
PCT has been FACT accredited at its Mountain View, California
facility and now at its new, state-of-the-art facility located in
Allendale, New Jersey. Additionally, PCT has obtained AABB
accreditation in the category
‘/>”/>
SOURCE
